Specialty Pharmacy

Top news of the day from across the health care landscape.

Pembrolizumab (Keytruda, Merck) plus chemotherapy met the primary endpoint of pathological complete response in patients with triple-negative breast cancer in a phase 3 study.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The findings represent the first positive phase 2b study of a personalized cancer vaccine in patients with high-risk melanoma.

With specialty pharmacy emerging as the fastest growing segment of the pharmacy industry, health systems have to address a key question: can you scale for it?

Study provides the longest available follow-up on the survival of patients with advanced melanoma, renal cell carcinoma, and non-small cell lung cancer treated with nivolumab.

Top news of the day from across the health care landscape.

Darolutamide is an androgen receptor inhibitor (ARi) for the treatment of patients with non-metastatic castration-resistant prostate cancer.

Abemaciclib (Verzenio, Eli Lilly) in combination with fulvestrant demonstrated a statistically significant improvement in overall survival among women with metastatic breast cancer previously treated with endocrine therapy.

Vaccine found to provide durable protection against the “death star” HIV strain, which is notably hard to fight.

Researchers aimed to determine the potential pathology of encephalitis as a complication of immunotherapy treatment.

Top news of the day from across the health care landscape.

Erdafitinib (Balversa, Janssen) is the first FGFR inhibitor to receive FDA approval for the treatment of patients with metastatic bladder cancer marked by FGFR gene mutations.

Top news of the day from across the health care landscape.

Administered through a drug-eluting implant, islatravir demonstrated protection against HIV for up to 12 months.

Results from an ongoing safety trial of tofacitinib demonstrated an increased risk of blood clots and death associated with a 10-mg twice daily dose of tofacitinib in patients with rheumatoid arthritis.

Top news of the day from across the health care landscape.

Investigators find that radiation equivalent to 3 CT scans prompts the growth of the p53 mutation in mice.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

If approved, tazemetostat, a first-in-class EZH2 inhibitor, would be indicated for the treatment of metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.

More colorectal cancer cases are being diagnosed in adults under the age of 50, with younger adults presenting with more advanced disease than those older than 50 years.

Long-term use of ivacaftor and other drugs that correct detects in the cystic fibrosis gene could potentially prevent chronic infections from developing.

Top news of the day from across the health care landscape.

Stigma around behaviors such as smoking or drinking found to effect funding for associated cancers.

There are currently no approved therapies for methylmalonic acidemia, a rare and life-threatening disease caused by mutations in the MUT gene.

Top news of the day from across the health care landscape.

Rituximab-pvvr (Ruxience, Pfizer) is approved for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.